8.30am - 4.30pm EDT | 5.30am - 1.30pm PDT

8:30 am

Coffee & Networking

8:55 am Chair’s Opening Remarks

The Role of Complement in COVID-19

9:00 am Nomacopan and COVID-19

9:30 am Potential Role of C5a-elicited Inflammation in COVID-19 Pathogenesis

10:00 am Hyperactivation of the Complement System in SARS-CoV-2 Infection and COVID-19

  • Michele Mercuri Therapeutic Area Head, Metabolics Clinical Development, Alexion

10:30 am

Morning Refreshments & Scientific Poster Session

Complement Clinical Advances in 2020

11:30 am Analysis of Complement in of Donor/Post-Mortem Eyes With & Without Age-Related Macular Degeneration (AMD), Implications for Future Intermediate AMD or Geographic Atrophy (GA) Clinical Trials

  • Stephen Poor Director , Novartis Institutes for Biomedical Research
  • Sha-mei Liao Senior Scientist, Novartis Institutes for Biomedical Research

12:00 pm Leveraging Biomarkers to De-risk Clinical Development in Complement Mediated Diseases: Progress with Anti-C1q Inhibitor ANX005

12:30 pm

Networking Lunch

1:30 pm Narsoplimab for the Treatment of Hematopoietic Stem Cell Transplant- Associated Thrombotic Microangiopathy

2:00 pm Sutimlimab in CAD

2:30 pm

Afternoon Refreshments

3:00 pm Complement Inhibition in Neurology

  • Laura Gault Therapeutic Area Head for Neurology Clinical Development, Alexion

3:30 pm Targeted C3 Therapy, Pegcetacoplan, has the Potential to Elevate the Standard of Care in PNH

4:00 pm Chair’s Closing Remarks & End of Conference